Table 5.
Dose-response relationship between HIV risk level and continuous TFV-DP and TFV concentrations in the HPTN 082 cohort
| DBS TFV-DP (N=371) | Plasma TFV (N=413) | |||||||
|---|---|---|---|---|---|---|---|---|
| Mean (SD) TFV-DP Concentration, fmol/punch | β (95% CI)2 | p-value | Global p-value | Mean (SD) TFV Concentration, ng/mL | β (95% CI)2 | p-value | Global p-value | |
| 0 HIV risk factors1 | 247.8 (369.5) | REF | --- | <0.0001 | 32.4 (66.0) | REF | --- | <0.0001 |
| 1 HIV risk factor | 291.0 (415.9) | 54.0 (−7.3-115.2) | 0.081 | 46.0 (81.1) | 12.6 (2.2-22.9) | 0.017 | ||
| 2 HIV risk factors | 322.9 (441.4) | 94.5 (16.7-172.4) | 0.017 | 46.8 (83.7) | 9.6 (−4.5-21.7) | 0.199 | ||
| ≥3 HIV risk factors | 447.1 (530.3) | 223 (125.0-321.8) | <0.0001 | 65.6 (99.3) | 28.6 (12.6-44.7) | <0.0001 | ||
DBS=dried blood spot; TFV-DP=tenofovir diphosphate; TFV=tenofovir; SD=standard deviation; 95% CI=95% confidence interval
1
HIV risk factors included report of condomless sex, ≥1 sexual partner, partner HIV status and antiretroviral therapy use, transactional sex, drug and alcohol use around sex, and laboratory confirmed sexually transmitted infections in the prior three months.
2
Multivariable models adjusted for study site and randomized arm